Processing

Please wait...

Settings

Settings

Goto Application

1. WO2018130702 - IMPROVED MULTI TYROSINE KINASE INHIBITOR THERAPY

Publication Number WO/2018/130702
Publication Date 19.07.2018
International Application No. PCT/EP2018/050941
International Filing Date 16.01.2018
IPC
A61K 45/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
CPC
A61K 31/496
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 11/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V. [DE]/[DE]
Inventors
  • PRASSE, Antje
Agents
  • ALTMANN STÖSSEL DICK PATENTANWÄLTE PARTG MBB
Priority Data
17151584.416.01.2017EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) IMPROVED MULTI TYROSINE KINASE INHIBITOR THERAPY
(FR) POLYTHÉRAPIE AMÉLIORÉE À BASE D'UN INHIBITEUR DE LA TYROSINE KINASE
Abstract
(EN)
The present invention relates tot he field of therapeutics and diagnostics. In particular, the present invention relates to a pharmaceutical composition or kit comprising (i) at least one CXCR4 inhibitorand (ii) a multi-tyrosine kinase inhibitor. It further contemplates a composition comprising at least one CXCR4 inhibitor for use in the treatment of cancer or idiopathic pulmonary fibrosisin a subject suffering from said cancer or idiopathic pulmonary fibrosis,wherein the subject is receiving a multi-tyrosine kinase inhibitor therapy. Moreover, encompassed by the present invention is a method for identifying whether a subject suffering from cancer or idiopathic pulmonary fibrosisand receiving a multi-tyrosine kinase inhibitor therapy is susceptible to a CXCR4 inhibitortherapy comprising the steps of determining the CXCR4 signal intensity in a PET dataset obtained from said subject, comparing said CXCR signal intensity to a reference, and identifying whether a subject suffering from cancer or idiopathic pulmonary fibrosisand receiving a multi-tyrosine kinase inhibitor therapy is susceptible for a CXCR4 inhibitortherapy based on the results of the comparison.
(FR)
La présente invention concerne le domaine de la thérapeutique et du diagnostic. En particulier, la présente invention concerne une composition pharmaceutique ou un kit comprenant (i) au moins un inhibiteur de CXCR4 et (ii) un inhibiteur multi-tyrosine kinase. L'invention concerne en outre une composition comprenant au moins un inhibiteur de CXCR4 destinée à être utilisée dans le traitement du cancer ou de la fibrose pulmonaire idiopathique chez un sujet souffrant dudit cancer ou de la fibrose pulmonaire idiopathique, le sujet recevant une thérapie à base d'un inhibiteur multi-tyrosine kinase. De plus, la présente invention concerne une méthode pour identifier si un sujet souffrant d'un cancer ou d'une fibrose pulmonaire idiopathique et recevant une thérapie à base d'un inhibiteur multi-tyrosine kinase est sensible à une thérapie inhibitrice de CXCR4 comprenant les étapes consistant à déterminer l'intensité du signal de CXCR4 dans un ensemble de données TEP obtenu à partir dudit sujet, à comparer ladite intensité de signal de CXCR avec une référence, et à identifier si un sujet souffrant d'un cancer ou d'une fibrose pulmonaire idiopathique et recevant une thérapie à base d'un inhibiteur multi-tyrosine kinase est sensible à une thérapie inhibitrice de CXCR4 sur la base des résultats de la comparaison.
Also published as
EP2018700361
Latest bibliographic data on file with the International Bureau